EP
HAE icon

Edgestream Partners’s Haemonetics HAE Stock Holding History

Edgestream Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,420
Closed -$2.2M – 963
2025
Q4 		$2.2M Buy
+27,420
New +$1.84M 0.06% 504
2024
Q2 		– Sell
-20,187
Closed -$1.72M – 921
2024
Q1 		$1.72M Buy
+20,187
New +$1.58M 0.09% 368
2023
Q4 		– Sell
-2,945
Closed -$264K – 928
2023
Q3 		$264K Buy
+2,945
New +$263K 0.02% 741
2022
Q3 		– Sell
-31,440
Closed -$2.05M – 518
2022
Q2 		$2.05M Buy
31,440
+11,354
+57% +$672K 0.16% 199
2022
Q1 		$1.27M Sell
20,086
-2,211
-10% -$120K 0.1% 288
2021
Q4 		$1.18M Buy
+22,297
New +$1.36M 0.07% 291

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Edgestream Partners's HAE Position: Q1 2026 in Review

Edgestream Partners sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 27,420 shares — an estimated $2.2M sold.

Edgestream Partners first reported a position in HAE in Q4 2021 and held it in 6 quarters. The position peaked at $2.2M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Edgestream Partners reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
  • Edgestream Partners sold 27,420 Haemonetics shares in Q1 2026, an estimated $2.2M.
  • Edgestream Partners first reported a position in Haemonetics in Q4 2021 and held it in 6 quarters.
  • Edgestream Partners's Haemonetics position peaked at $2.2M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.